Record mula sa primary source
Decision-gradePag-apruba ng FDA
Outlook Therapeutics, Inc. · Inaprubahan ng FDA ang Lytenava (bevacizumab-vikg)
Inilista ng FDA ang Lytenava (bevacizumab-vikg) bilang bagong pag-apruba ng gamot #28 ng 2026 noong 2026-07-24: Upang gamutin ang mga pasyente na may neovascular (wet) age-related macular degeneration
Mahahalagang fact
- Na-file
- Hul 24, 2026, 12:00 AM
- Kaganapan
- Pag-apruba ng FDA
- Direksyon
- Positibo
- Kumpanya
OTLKOutlook Therapeutics, Inc.- Asset
- bevacizumab-vikg
- Pinagmulan
- FDA Novel Drug Approvals
- Kumpiyansa
- May source
Higit pa tungkol sa asset na ito
Decision-grade
Hul 24, 2026
09:01 PM
OTLKOutlook Therapeutics, Inc.Materyal
Hun 16, 2026
12:46 PM
OTLKOutlook Therapeutics, Inc.Materyal
Hun 16, 2026
12:02 PM
OTLKOutlook Therapeutics, Inc.Materyal
Hun 1, 2026
01:15 PM
OTLKOutlook Therapeutics, Inc.Materyal
Hun 1, 2026
12:46 PM
OTLKOutlook Therapeutics, Inc.Decision-grade
May 26, 2026
11:15 AM
OTLKOutlook Therapeutics, Inc.Materyal
Abr 7, 2026
08:15 PM
OTLKOutlook Therapeutics, Inc.Decision-grade
Dis 19, 2025
01:30 PM
OTLKOutlook Therapeutics, Inc.